Notably, both miR‐19a‐3p overexpression and TGF‐β antibody antagonism may serve as promising therapeutic strategies to reverse CD4+ T cell suppression and ameliorated the prognosis of HBV‐related DLBCL. Here, TGFB1 is linked to diffuse large B-cell lymphoma.